This narrative review explores how signals from muscles, called myokines, interact with cancer and muscle wasting. The study looked at specific signals like myostatin, interleukin-6, and others to understand their roles in disease. Because this is a review of existing information rather than a new clinical trial, the findings represent a collection of current knowledge rather than new proof from a single experiment.
The analysis found that these muscle signals play a dual role, acting either to help or hinder cancer depending on the specific environment. Some signals showed potential to fight tumors by blocking key growth pathways, while others influenced how cancer cells interact with surrounding tissue. Additionally, certain signals appeared in higher amounts in patients with specific cancers, suggesting they might serve as useful markers for diagnosis and predicting disease course.
The review also highlighted promising possibilities for treating cancer-related muscle loss and wasting. Inhibiting specific signals like myostatin could help relieve these symptoms, while combining treatments that block interleukin-6 with other cancer therapies might create a stronger, synergistic effect. However, the authors note that the exact link between these signals and muscle wasting needs deeper investigation. While these findings offer new ideas for improving survival and protecting muscle function, they are not yet ready to change standard medical practice.